Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Bearish
5
Neutral
3
Bullish
6
Bearish
5
Neutral
3
Bullish
38
Bearish
0
Neutral
0
Bullish
32
Discovery themes featuring this stockDiscover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Viyash Scientific Limited, formerly Sequent Scientific Limited, is engaged in the pharmaceutical business with a focus on animal health, formulations, and API. The company has shown solid financial performance in Q3 FY26, with revenues of ₹8,584 million and EBITDA growing by 64% YoY. It has achieved significant margin expansion, reflecting strong operational efficiencies and strategic cost optimization.
The merger with Sequent Scientific Limited has enabled Viyash to unlock synergies across various business units, enhancing R&D, manufacturing capabilities, and market reach. This transformative merger has laid a strong foundation for sustained profitability and business growth.
Viyash has successfully entered into strategic partnerships, including a noteworthy agreement with Boehringer Ingelheim for distributing companion animal products in India, underscoring its commitment to expanding its footprint in the animal health sector.
The company is focusing on expanding its R&D capabilities, emphasizing the development of complex generics, which positions it to capture significant opportunities in the growing generics market for companion animals.
Pharmaceuticals & Biotechnology
Pharmaceuticals
9,102 Cr
High Risk
120.1
32.2
0.8
10.8
260.30
141.80
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stockViyash Scientific Ltd (VIYASH) is currently trading at 209.60 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Viyash Scientific Limited, formerly Sequent Scientific Limited, is engaged in the pharmaceutical business with a focus on animal health, formulations, and API. The company has shown solid financial performance in Q3 FY26, with revenues of ₹8,584 million and EBITDA growing by 64% YoY. It has achieved significant margin expansion, reflecting strong operational efficiencies and strategic cost optimization. The merger with Sequent Scientific Limited has enabled Viyash to unlock synergies across various business units, enhancing R&D, manufacturing capabilities, and market reach. This transformative merger has laid a strong foundation for sustained profitability and business growth. Viyash has successfully entered into strategic partnerships, including a noteworthy agreement with Boehringer Ingelheim for distributing companion animal products in India, underscoring its commitment to expanding its footprint in the animal health sector. The company is focusing on expanding its R&D capabilities, emphasizing the development of complex generics, which positions it to capture significant opportunities in the growing generics market for companion animals.
Over the past 52 weeks, Viyash Scientific Ltd has traded between a low of ₹141.80 and a high of ₹260.30. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Viyash Scientific Ltd has a market capitalization of approximately 9,102.13. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Viyash Scientific Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 120.13 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 9,102.13 Cr, Viyash Scientific Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Viyash Scientific Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Viyash Scientific Ltd is 120.13. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The loan-linked subsidy scheme for the private veterinary sector and the ₹10,000 crore 'Biopharma Shakti' initiative are the two most significant announcements, as they directly expand the company's market and strengthen the entire pharmaceutical ecosystem.
Credit Rating
ICRA assigned a [ICRA]AA- (Stable) rating to Viyash Scientific Limited’s long‑term fund‑based working capital facilities of Rs.185.00 crore (ICICI Rs.35cr; Kotak Rs.150cr), communicated Apr 22, 2026; this is higher than the prior IND A rating.
Director appointments
Board approved appointment of Mr. Amit Jain and Mr. Abhiroop Jayanthi as Additional Non-Executive, Non-Independent Directors representing Carlyle effective Apr 22, 2026 (subject to shareholder approval), and reduced ESOP 2026 pool to 13,098,000 options from 13,475,000.
Board Appointments & ESOP
Board approved appointment of Amit Jain and Abhiroop Jayanthi as Additional Non‑Executive, Non‑Independent Directors (representing Carlyle) and a revised ESOP 2026 pool of 13,098,000 options (from 13,475,000), effective April 22, 2026, subject to shareholder approval.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1625.00 | 9,885 Cr | 66.52 | 14.99 | 0.45 | 26.53 | 33.34 | 17.54 | ||
1004.00 | 9,196 Cr | 18.09 | 3.34 | 0.40 | 14.42 | 14.96 | 8.14 | ||
208.85 | 9,102 Cr | 120.13 | 10.76 | 0.00 | 15.22 | 18.17 | 8.65 | ||
4931.05 | 8,442 Cr | 27.89 | 13.62 | 2.46 | 49.51 | 65.17 | 32.81 | ||
497.00 | 8,406 Cr | 23.92 | 2.67 | 0.00 | 10.07 | 8.99 | 6.29 | ||
654.95 | 8,403 Cr | 26.37 | 23.76 | 0.16 | 42.02 | 46.06 | 36.87 | ||
3380.10 | 8,112 Cr | 19.65 | 9.43 | 3.49 | 42.11 | 52.41 | 25.64 | ||
| Median: 7 Co. | — | 1004.00 | 8,442 Cr | 26.37 | 10.76 | 0.40 | 26.53 | 33.34 | 17.54 |
